| Next 10 |
Ad
TCBP News and Press TC BioPharm (Holdings) plc
-
TC BioPharm to Host Shareholder Update Call PR Newswire Conference Call to be held on Monday, February 20 th , 2023 at 10:00 am ET EDINBURGH, Scotland , Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Compan...
-
TC Biopharm ( NASDAQ: TCBP ) has received Nasdaq notice indicating the company has not regained compliance with the rule of $35M minimum market value of listed securities. The company on July 15,2022 had received written Nasdaq notice indicating that the company wa...
-
Palm Beach, FL – January 19, 2023 – FinancialNewsMedia.com News Commentary – Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based immunotherapy has greatly revolutionized the par...
-
TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1) PR Newswire EDINBURGH, Scotland , Jan. 19, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), has received writte...
-
TC Biopharm ( NASDAQ: TCBP ) is trading 18.5% higher premarket after it announced a strategic collaboration with The University of Texas MD Anderson Cancer Center to test on how gamma-delta T cells work in oncology settings. Under the collaboration, MD Anderson's clinical tria...
-
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology PR Newswire Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland , Jan. 17, 2023 /PRNewswire/ -- TC B...
-
TC Biopharm press release ( NASDAQ: TCBP ): 1H GAAP EPS of $1.13. Revenue of $1.2M. Cash and cash equivalents were £6.0 million or $7.3 million as of June 30, 2022 compared to £1.6 million as of December 31, 2021. For further details see: TC Biopharm GAAP E...
-
TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update PR Newswire Dosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML). ...
-
TC BioPharm Announces Closing of $7.35 Million Private Placement PR Newswire EDINBURGH, Scotland , Nov. 30, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company dev...
-
TC BioPharm Announces $7.35 Million Private Placement PR Newswire EDINBURGH, Scotland , Nov. 28, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company d...
Stock Information
TC BioPharm (Holdings) plc Company Name:
TCBP Stock Symbol:
NASDAQ Market:
Get TCBP Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
